{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:33:36Z","timestamp":1790163216045,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.esmoop.2024.103987","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T20:43:16Z","timestamp":1731703396000},"page":"103987","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["HER2DX genomic test in early-stage HER2-positive breast cancer"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-8671","authenticated-orcid":false,"given":"S.M.","family":"Tolaney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3734-1063","authenticated-orcid":false,"given":"A.C.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"DeMichele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Cejalvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Mart\u00ednez-S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8431-3183","authenticated-orcid":false,"given":"T.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.G.","family":"Waks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9237-3231","authenticated-orcid":false,"given":"M.","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ciruelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9744-7372","authenticated-orcid":false,"given":"N.","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2388-4649","authenticated-orcid":false,"given":"L.A.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-1583","authenticated-orcid":false,"given":"J.","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"G.","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-540X","authenticated-orcid":false,"given":"A.","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2024.103987_bib1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.breast.2021.07.019","article-title":"Dissecting the biological heterogeneity of HER2-positive breast cancer","volume":"59","author":"Schettini","year":"2021","journal-title":"Breast"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103987_bib2","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41571-024-00939-2","article-title":"Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance","volume":"21","author":"Waks","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103987_bib3","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1007\/s12094-024-03409-4","article-title":"Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey","volume":"26","author":"Mart\u00ednez-S\u00e1ez","year":"2024","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103987_bib4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103987_bib5","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1007\/s12094-023-03203-8","article-title":"SEOM\u2013GEICAM\u2013SOLTI clinical guidelines in advanced breast cancer (2022)","volume":"25","author":"Garcia-Saenz","year":"2023","journal-title":"Clin Transl Oncol"},{"issue":"37","key":"10.1016\/j.esmoop.2024.103987_bib6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/EDBK_175630","article-title":"Optimal management of early and advanced HER2 breast cancer","author":"Hurvitz","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.esmoop.2024.103987_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103801","article-title":"Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer","volume":"75","author":"Prat","year":"2022","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103987_bib8","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/annonc\/mdy414","article-title":"Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study","volume":"29","author":"Conte","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.103987_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103011","article-title":"1MO - HER2DX assay and survival outcomes: an individual-patient level meta-analysis of 2,031 patients with HER2-positive breast cancer","volume":"9","author":"Javierre","year":"2024","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103987_bib10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1470-2045(23)00051-7","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial","volume":"24","author":"Tolaney","year":"2023","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103987_bib11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.annonc.2023.05.012","article-title":"Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer","volume":"34","author":"Villacampa","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103987_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102388","article-title":"Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B)","volume":"9","author":"Villacampa","year":"2024","journal-title":"ESMO Open"},{"issue":"18","key":"10.1016\/j.esmoop.2024.103987_bib13","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1158\/1078-0432.CCR-24-0464","article-title":"HER2DX genomic assay in HER2-positive early breast cancer treated with trastuzumab and pertuzumab: a correlative analysis from the PHERGain phase II trial","volume":"30","author":"Llombart-Cussac","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103987_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.02170","article-title":"Adjuvant trastuzumab emtansine versus paclitaxel plus trastuzumab for stage I human epidermal growth factor receptor 2-positive breast cancer: 5-year results and correlative analyses from ATEMPT","author":"Tarantino","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 9","key":"10.1016\/j.esmoop.2024.103987_bib15","article-title":"Abstract PS09-02: Event-free survival by residual cancer burden (RCB) and intratumor HER2 heterogeneity after neoadjuvant T-DM1 and pertuzumab for early-stage HER2-positive breast cancer","volume":"84","author":"Metzger","year":"2024","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103987_bib16","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jamaoncol.2023.0181","article-title":"Assessment of the HER2DX assay in patients with ERBB2-positive breast cancer treated with neoadjuvant paclitaxel, trastuzumab, and pertuzumab","volume":"9","author":"Waks","year":"2023","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103987_bib17","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2023.0187","article-title":"Assessment of a genomic assay in patients with ERBB2-positive breast cancer following neoadjuvant trastuzumab-based chemotherapy with or without pertuzumab","volume":"9","author":"Bueno-Mui\u00f1o","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103987_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101231","article-title":"7P - Independent validation of HER2DX ERBB2 mRNA score to predict HER2-positive (HER2+), HER2-low and HER2-0 status in breast cancer","volume":"8","author":"Torres","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2024.103987_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104320","article-title":"HER2DX genomic test in HER2-positive\/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: a correlative analysis from the PerELISA trial","volume":"85","author":"Guarneri","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.esmoop.2024.103987_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103022","article-title":"13P - HER2DX ERBB2 mRNA score in first-line metastatic HER2-positive (HER2+) breast cancer (BC): implications for treatment stratification","volume":"9","author":"Bayona","year":"2024","journal-title":"ESMO Open"},{"issue":"13","key":"10.1016\/j.esmoop.2024.103987_bib21","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.20.01204","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years' follow-up","volume":"39","author":"Piccart","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103987_bib22","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/cncr.34750","article-title":"Nodal positivity and systemic therapy among patients with clinical T1\u2013T2N0 human epidermal growth factor receptor-positive breast cancer: results from two international cohorts","volume":"129","author":"Weiss","year":"2023","journal-title":"Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924017575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924017575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T23:43:22Z","timestamp":1736293402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924017575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2059702924017575"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103987","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2DX genomic test in early-stage HER2-positive breast cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103987","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103987"}}